Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA; Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators. Teoh H, et al. Among authors: mendelsohn aa. Am J Cardiol. 2009 Sep 15;104(6):798-804. doi: 10.1016/j.amjcard.2009.05.019. Epub 2009 Jul 23. Am J Cardiol. 2009. PMID: 19733714
Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC).
Katz PM, Mendelsohn AA, Goodman SG, Langer A, Teoh H, Leiter LA. Katz PM, et al. Among authors: mendelsohn aa. Can J Cardiol. 2011 Mar-Apr;27(2):138-45. doi: 10.1016/j.cjca.2010.12.010. Can J Cardiol. 2011. PMID: 21459260
Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy.
Tsang JL, Mendelsohn A, Tan MK, Hackam DG, Leiter LA, Fitchett D, Lin PJ, Grima E, Langer A, Goodman SG; Vascular Protection Registry and Guidelines Oriented Approach to Lipid Lowering Registry Investigators. Tsang JL, et al. Am J Cardiol. 2008 Nov 1;102(9):1142-5. doi: 10.1016/j.amjcard.2008.06.037. Epub 2008 Aug 15. Am J Cardiol. 2008. PMID: 18940280
Prognostic significance of admission heart failure in patients with non-ST-elevation acute coronary syndromes (from the Canadian Acute Coronary Syndrome Registries).
Segev A, Strauss BH, Tan M, Mendelsohn AA, Lai K, Ashton T, Fitchett D, Grima E, Langer A, Goodman SG; Canadian Acute Coronary Syndrome Registries Investigators. Segev A, et al. Among authors: mendelsohn aa. Am J Cardiol. 2006 Aug 15;98(4):470-3. doi: 10.1016/j.amjcard.2006.03.023. Epub 2006 Jun 19. Am J Cardiol. 2006. PMID: 16893699
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG; INTERACT Trial Long-Term Follow-Up Investigators. Fitchett DH, et al. Am Heart J. 2006 Feb;151(2):373-9. doi: 10.1016/j.ahj.2005.05.003. Am Heart J. 2006. PMID: 16442903 Clinical Trial.
Missed opportunities for the secondary prevention of cardiovascular disease in Canada.
Hackam DG, Leiter LA, Yan AT, Yan RT, Mendelsohn A, Tan M, Zavodni L, Chen R, Tsang JL, Kundi A, Lin PJ, Fitchett DH, Langer A, Goodman SG; Vascular Protection Registry and Guideline Oriented Appraoch to Lipid Lowering Registry Investigators. Hackam DG, et al. Can J Cardiol. 2007 Dec;23(14):1124-30. doi: 10.1016/s0828-282x(07)70882-6. Can J Cardiol. 2007. PMID: 18060097 Free PMC article.
12 results